Cayman Islands vs Fiji: Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology
Cayman Islands
0.2%
in 2024
Fiji
0.2%
in 2024
Cayman Islands rank
78th
Fiji rank
78th
Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology over time
- Cayman Islands
- Fiji
How they compare
Cayman Islands currently reports 0.2% against 0.2% in Fiji, a difference of 0.0%.
The two have swapped places 3 times across 10 shared years of data; in 2015 it was Cayman Islands ahead.
Cayman Islands ranks 78th and Fiji ranks 78th of 215 countries.
Across the 2 decades both report, Cayman Islands averaged higher in 1 and Fiji in 1.
Head to head by decade
| Decade | Cayman Islands | Fiji | Difference | Ahead |
|---|---|---|---|---|
| 2010s | 0.3% | 0.3% | 0.0% | Cayman Islands |
| 2020s | 0.2% | 0.3% | 0.1% | Fiji |
Averages of every year both report within each decade.
Frequently asked questions
- Which has higher prevalence of hepatitis b surface antigen (hbsag), 2026 methodology, Cayman Islands or Fiji?
- Cayman Islands, at 0.2% against 0.2% in Fiji as of 2024.
- What is the difference in prevalence of hepatitis b surface antigen (hbsag), 2026 methodology between Cayman Islands and Fiji?
- 0.0%, with Cayman Islands ahead.
- How many years of comparable data are there for Cayman Islands and Fiji?
- 10 years are reported by both, from 2015 to 2024.
- How do Cayman Islands and Fiji rank globally for prevalence of hepatitis b surface antigen (hbsag), 2026 methodology?
- Cayman Islands ranks 78th and Fiji ranks 78th of 215 countries.
- Where does this data come from?
- United Nations Statistics Division, SDG Global Database, published as Prevalence of hepatitis B surface antigen (HBsAg), 2026 methodology (%). Statizoid refreshes it automatically from the source and publishes the full history for both places.